Medical Oncology

Genomic Testing

Questions discussed in this category

Which patients with Stage II-III lung adenocarcinoma, in whom you are considering neoadjuvant chemoimmunotherapy, can you rely on liquid NGS to exclude driver mutations in lieu of repeat tissue biopsy?

Per NCCN exclusion of EGFR/ALK alterations at a minimum is recommended prior to consideration of neoadjuvant chemoimmunotherapy.

1 Answer available

Does cytotoxic chemotherapy affect the yield of germline testing?

Should testing for germline mutations -- eg. saliva sample -- occur before or after the completion of chemotherapy - or the timing does not matter?&nb...

1 Answer available

Is there any role for re-biopsy and NGS for patients with NSCLC and KRAS G12C at time of progression after first line therapy before starting sotorasib, or after progression on sotorasib?

1 Answer available

Can you use NGS panels or ctDNA to help you find organ of origin in the workup of carcinoma of unknown origin?

If so, what alterations would be helpful to narrow the diagnosis?

1 Answer available

Papers discussed in this category

N Engl J Med, 2021 Jun 24

Acquired Resistance to KRAS^G12C Inhibition in Cancer.

J. Clin. Oncol., 2019 Jan 17

Randomized Phase II Trial Comparing Site-Specific Treatment Based on Gene Expression Profiling With Carboplatin and Paclitaxel for Patients With Cancer of Unknown Primary Site.

Mol Diagn Ther, 2023 Apr 26

Validation of a Transcriptome-Based Assay for Classifying Cancers of Unknown Primary Origin.

Transl Oncol, 2021 Jan 16

Machine learning analysis using 77,044 genomic and transcriptomic profiles to accurately predict tumor type.

Lancet Oncol, 2016 Aug 27

Epigenetic profiling to classify cancer of unknown primary: a multicentre, retrospective analysis.

ESMO Open, 2022 Dec 01

Complete genomic characterization in patients with cancer of unknown primary origin in routine diagnostics.

Nat Commun, 2022 Aug 02

Comprehensive genomic and epigenomic analysis in cancer of unknown primary guides molecularly-informed therapies despite heterogeneity.

Medical Oncology

Genomic Testing

Questions discussed in this category

Papers discussed in this category

Related Topics in Medical Oncology